Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

The Trade Desks steep slide to multi-year lows is fueling concern about softer advertising demand and competition from Amazon and other ad-tech platforms. Traders largely criticize management and expect further downside, while some bullish voices see an oversold value opportunity or potential rebound.

Iovances raised full-year revenue outlook, reflecting stronger demand for Amtagvi and Proleukin, is driving a sharp rally. Many traders view the update as validation of the commercial ramp and speculate about short covering, while others flag profit-taking or possible dilution; upcoming lung-cancer data is also a focus.

DraftKings is under pressure amid fears that Kalshi and Polymarket are taking wagering share and could squeeze sportsbook margins, with regulatory uncertainty around prediction markets adding to sector concerns. Bears see a lasting competitive threat and costly investment, while bulls point to rapid growth in DraftKings own DKeX prediction-market activity and its core sportsbook business.

FICO is plunging after the FHFA moved to include VantageScore alongside FICO in Fannie Mae and Freddie Mac mortgage pricing, raising concerns that competition could erode its scoring businesss longstanding advantage. Traders are split between expecting further pressure on pricing and market share and viewing the selloff as an overreaction, with some buying for a rebound.

Carnivals quarterly earnings beat and raised full-year outlook, supported by record customer deposits and strong 2027 bookings, drove a sharp rally. Bulls point to resilient cruise demand, while skeptics cite fuel costs, margin pressure and a weaker fourth-quarter earnings outlook.

uniQures Huntingtons disease gene therapy AMT-130 drew heavy attention after four-year data showed less slowing on the cUHDRS measure than at three years, with the four-year result not statistically significant, prompting a sharp selloff. Traders debate whether this raises concerns about durability or is an overreaction, since the FDA had agreed the BLA could rely on the stronger three-year data; some also question the four-year comparisons external controls and patient dropouts.

Upcoming staggered share unlocks and potential insider selling are the dominant concern, with traders linking the added supply to CBRSs sharp swings and debating whether demand can absorb it. Bullish traders point to Cerebrass AI-inference business and customer partnerships, while others cite broader risk-off conditions and caution about the stocks volatility.

A Bank of America upgrade and more optimistic outlook are driving Magnites sharp move, with traders welcoming the endorsement and increased volume. Bulls also cite potential benefits from Googles ad-tech remedies, while some caution that past upgrade rallies have faded and debate how quickly those remedies could affect revenue.

Voyagers newly formalized partnership with Anduril across weapons and propulsion is drawing attention, but shares are falling despite the positive development. Traders are debating whether financing and arbitrage-related overhang is weighing on the stock, while others are frustrated that the partnership has not sparked a stronger reaction.

AstraZenecas strategic investment in Summit and collaboration to study ivonescimab are driving attention, with traders viewing the deal as validation and relief on funding concerns while others focus on dilution and caution that it is not a buyout. The upcoming FDA decision on ivonescimab remains a separate catalyst in the discussion.